SKL24741 / SK Bio - LARVOL DELTA

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects (clinicaltrials.gov) - P1 | N=111 | Completed | Sponsor: SK Life Science, Inc. | Active, not recruiting ➔ Completed

Trial completion

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects (clinicaltrials.gov) - P1 | N=111 | Active, not recruiting | Sponsor: SK Life Science, Inc. | Recruiting ➔ Active, not recruiting | N=160 ➔ 111

Enrollment change • Enrollment closed

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects (clinicaltrials.gov) - P1 | N=160 | Recruiting | Sponsor: SK Life Science, Inc. | N=98 ➔ 160 | Trial completion date: Mar 2022 ➔ Dec 2022 | Trial primary completion date: Oct 2021 ➔ Dec 2022

Enrollment change • Trial completion date • Trial primary completion date

From prevention and treatment to management…SK Biopharmaceutical Strengthens CNS Expertise [Google translation] (Economic Review) - "SK Biopharmaceuticals (326030) is strengthening its expertise in the central nervous system (CNS) field from prevention and treatment to management. Sales of the self-developed epilepsy treatment 'Cenobamate (US name: Xcopri)' are growing in earnest in the US....Cenobamate recorded 31.7 billion won in sales in the US in the first quarter of this year....SKL24741, a new drug candidate for next-generation epilepsy, and SKL20540, a new drug candidate for schizophrenia are expected to enter phase 2 clinical trials within this year."

New P2 trial • Sales • CNS Disorders • Epilepsy